Document is current
Any future updates will be listed below
-
Authors
Makishima, Hideki https://orcid.org/0000-0001-5983-8578
Mikasa, Taisuke
Isogaya, Kento
Miyamoto, Toshihiro
Yamauchi, Takuji
Yokota, Akira
Onozawa, Masahiro
Ando, Kiyoshi
Ogawa, Yoshiaki
Usuki, Kensuke
Yamauchi, Takahiro
Ota, Shuichi
Takada, Satoru
Morita, Yasuyoshi
Ishikawa, Takayuki
Takenaka, Katsuto
Kuroda, Junya
Sekiguchi, Naohiro
Kawakita, Toshiro
Miyazaki, Yasushi
-
Funding
Funding for this research was provided by:
Nippon Shinyaku
- License Information
-
More Information
Article History
Received: 16 December 2024
Revised: 14 February 2025
Accepted: 16 February 2025
First Online: 27 February 2025
Declarations
:
: NS-87/CPX-351 was provided by Nippon Shinyaku Co., Ltd. MH reports research funding of the submitted study from Nippon Shinyaku Co., Ltd. MT and IK are employees of Nippon Shinyaku Co., Ltd. MT reports honoraria from Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., and Abbvie Inc. OM reports consulting fees from Janssen Pharmaceutical K.K. and Daiichi Sankyo Co., Ltd., and honoraria from Astellas Pharma Inc., Abbvie Inc., Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Lt., Novartis Pharma K.K., Nippon Shinyaku Co., Ltd., and Kyowa Kirin Co., Ltd. AK reports grants from Takeda Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Eisai Co., Ltd., and honoraria from Janssen Pharmaceutical K.K., Meiji Seika Pharma Co., Ltd., Nippon Shinyaku Co., Ltd., Bristol-Myers-Squibb K.K., Eisai Co., Ltd., and Ono Pharmaceutical Co., Ltd. OY reports grants from Mochida Pharmaceutical CO., LTD., Janssen Pharmaceutical K.K., Abbvie Inc., Otsuka Pharmaceutical Co., Ltd., FUJIFILM Pharmaceuticals Inc., and Fortrea Japan Inc., and honoraria from Novartis Pharma K.K., Chugai Pharmaceutical Co., Ltd., Novo Nordisk K.K., AstraZeneca K.K., Daiichi Sankyo Co., Ltd., and Abbvie Inc. UK reports grants from Agios Pharmaceuticals Inc., Astellas Pharma Inc., Abbvie Inc., Alexion Pharmaceuticals, Inc., Aperis LLC., Asahi Kasei Pharma Corp., Bristol-Myers-Squibb K.K., Celgene Corp., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Gilead Sciences Inc., Incyte Corp., Kyowa Kirin Co., Ltd., MSD Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., OHARA Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., PharmaEssentia Corp., Pfizer Japan Inc., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., and Yakult Honsha Co., Ltd., consulting fees from Alnylam Japan K.K., OHARA Pharmaceutical Co., Ltd., and Chugai Pharmaceutical Co., Ltd., and honoraria from Abbvie Inc., Alexion Pharmaceuticals, Inc., Amgen Inc., Astellas Pharma Inc., Asahi Kasei Pharma Corp., AstraZeneca K.K., Bristol-Myers-Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Incyte Corp., Kyowa Kirin Co., Ltd., Meiji Seika Pharma Co., Ltd., Novartis Pharma K.K., Sanofi K.K., Nippon Shinyaku Co., Ltd., Ono Pharmaceutical Co., Ltd.,　Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sandoz International GmbH, PharmaEssentia Corp., Takeda Pharmaceutical Co., Ltd., and Janssen Pharmaceutical K.K., and leadership in Japan Adult Leukemia Study Group. YT reports honoraria from Nippon Shinyaku Co., Ltd. OS reports honoraria from Novartis Pharma K.K., Bristol-Myers-Squibb K.K., Takeda Pharmaceutical Co., Ltd., AstraZeneca K.K., Janssen Pharmaceutical K.K., Abbvie Inc., Amgen Inc., Sanofi K.K., and PharmaEssentia Corp. KJ reports grants from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical co., Ltd., Sumitomo Pharma Co., Ltd., Japan Blood Product Organization, Bristol-Myers-Squibb K.K., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Ono Pharmaceutical Co., Ltd., OHARA Pharmaceutical Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., GlaxoSmithKline K.K., and Meiji Seika Pharma Co., Ltd., and consulting fees from Janssen Pharmaceutical K.K., Abbvie Inc., Pfizer Japan Inc., BeiGene Co., Ltd., and Bristol-Myers-Squibb K.K., and honoraria from Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Bristol-Myers-Squibb K.K., Novartis Pharma K.K., Abbvie Inc., Pfizer Japan Inc., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Genmab K.K., and PharmaEssentia Corp. SN reports honoraria from Janssen Pharmaceutical K.K. and Ono Pharmaceutical Co., Ltd., and research funding from Incyte Corp., MSD Co., Ltd., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma co., Ltd. MY reports research funding of the submitted study from Nippon Shinyaku Co., Ltd., honoraria from Novartis Pharma K.K., Abbvie Inc., Bristol-Myers-Squibb K.K., Chugai Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Astellas Pharma Inc., and Daiichi Sankyo Co., Ltd., and participation on a data safety monitoring board or advisory board at Sumitomo Pharma Co., Ltd., and leadership in Japan Adult Leukemia Study Group and an Associate Editor of International Journal of Hematology.
